Providers

The study found no difference in physician communication scores between patients with advanced cancer and other illnesses, suggesting that discordance may stem from other dynamics.

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) disease activity.

Ravi Vij, MD, MBA, explains how insurance-related delays in CAR T approval slow treatment initiation, increase interim therapy costs, and contribute to patient burden.

Clonally expanded CD8+ T cells appear to play a causal role in the initiation and progression of alopecia areata.

Investigators believe the SWIFT-seq system holds potential to replace more invasive bone marrow biopsies.

Patients reported quality-of-life benefits from treatment for nonsegmental vitiligo, even when clinical improvement started slowly.

Patients with chronic lymphocytic leukemia (CLL) had significantly lower monocyte-to-lymphocyte ratio values compared with healthy controls.

A qualitative study found strong support for primary care provider–nephrologist comanagement of chronic kidney disease (CKD), but persistent deficits in CKD understanding remain.

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

Patients with alopecia universalis and alopecia totalis are at a particularly high risk of cardiovascular disease, a new study has found.

Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.

Patients with myeloproliferative neoplasms (MPNs) appear to be at a higher risk of heart failure and pulmonary hypertension, though more research into the links is needed.

New drugs aren't the only advances in oncology. Innovation includes collaboration between to remove barriers to remove barriers to care, according to experts who gathered for a session of the Institute for Value-Based Medicine in Arlington, Virginia.

Men fared better under surveillance, while women benefited more from targeted therapies for the treatment of chronic lymphocytic leukemia (CLL) in a new study.

Cutting-edge cancer therapies and innovative care models that advance patient access and significantly reduce health care costs took center stage at the Institute of Value-Based Medicine (IVBM) event in Minneapolis, Minnesota.

Ravi Vij, MD, MBA, discusses the logistical differences between administering CAR T-cell therapy and bispecific antibodies, and how emerging CAR T technologies could affect patient access.

Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia gravis and being able to predict patients at risk of myasthenic crisis.

The FDA approved zopapogene imadenovec, the first therapy for recurrent respiratory papillomatosis, providing an option beyond repeated surgeries to manage the rare condition.

Approval was based on part 1 of the ESSENCE trial, with part 2 results expected in 2029.

Biologic therapies for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) significantly improved ear-related symptoms, enhancing patient quality of life and treatment outcomes.

Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.

Laxmi Patel, chief strategy officer at Savista, outlines major impacts of the “One Big Beautiful Bill” Act on Medicaid and what hospitals can do to prepare for these changes.

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Among patients who have myasthenia gravis, even low disease activity can impact their quality of life (QOL) via motor fatiguability.

As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, training, and collaborative frameworks needed for optimal management is a public health priority, emphasize the researchers.